Design Therapeutics (DSGN) Capital Expenditures (2020 - 2025)
Design Therapeutics recorded quarterly Capital Expenditures of $34000.0 in Q4 2025, down 60.92% quarter-over-quarter from $87000.0 in Q2 2025.
Design Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $34000.0 for Q4 2025.
- In Q4 2025, Capital Expenditures changed N/A year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $121000.0 (down 44.24% YoY), while the FY2025 annual figure was $193000.0, down 43.24% from the prior year.
- Capital Expenditures came in at $34000.0 for Q4 2025 at Design Therapeutics, down from $87000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $968000.0 in Q3 2021 to a low of -$16000.0 in Q3 2024.
- A 5-year average of $180277.8 and a median of $88000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 2428.57% in 2021 and sank 130.19% in 2024, its largest moves.
- Design Therapeutics' Capital Expenditures stood at $354000.0 in 2021, then dropped by 18.64% to $288000.0 in 2022, then sank by 90.62% to $27000.0 in 2023, then tumbled by 159.26% to -$16000.0 in 2024, then surged by 312.5% to $34000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $34000.0, $87000.0, and $72000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34,000.00 |
| Dec 31, 2025 | 34,000.00 |
| Jun 30, 2025 | 87,000.00 |
| Jun 30, 2025 | 87,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Sep 30, 2024 | -16,000.00 |
| Sep 30, 2024 | -16,000.00 |
| Jun 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 161,000.00 |
| Mar 31, 2024 | 195,000.00 |
| Mar 31, 2024 | 195,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 53,000.00 |
| Sep 30, 2023 | 53,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Mar 31, 2023 | 87,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Sep 30, 2022 | 408,000.00 |
| Sep 30, 2022 | 408,000.00 |
| Jun 30, 2022 | 203,000.00 |
| Jun 30, 2022 | 203,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 354,000.00 |
| Dec 31, 2021 | 354,000.00 |
| Sep 30, 2021 | 968,000.00 |
| Sep 30, 2021 | 968,000.00 |
| Jun 30, 2021 | 183,000.00 |
| Jun 30, 2021 | 183,000.00 |
| Mar 31, 2021 | 33,000.00 |
| Mar 31, 2021 | 33,000.00 |
| Dec 31, 2020 | 14,000.00 |
| Dec 31, 2020 | 14,000.00 |